Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2013

View Archived Issues

Researchers uncover the mechanism behind malaria parasite sensitivity to spiroindolone-based drugs

Alemtuzumab treatment maintains efficacy in phase III extension study

Sernova receives Canadian funding for Sertolin technology

Pharmacodynamics of new rituximab biosimilar evaluated

Chinese researchers present new protein kinase inhibitors for cancer

Biovista and Dart Therapeutics enter collaboration

Researchers evaluate inflammatory and immune system biomarkers in chronic prostatitis

Omeros set to advance lead PDE10 inhibitor to phase II

Myriad Genetics to conduct HRD testing for PharmaMar

NICE recommends two treatments for lung infection in cystic fibrosis

Oncodesign to apply Nanocyclix technology to Sanofi kinase target

GNbAC-1 is safe and well tolerated in phase IIa trial

University of New Mexico to collaborate with Biosortia Pharmaceuticals

Soligenix cleared to begin phase II study of SGX-942

CureVac commences phase IIb trial of mRNA-based prostate cancer vaccine

A team of German researchers disclose novel antimalarial agents

Eisai obtains FDA approval for new formulation of AcipHex

Single nucleotide polymorphisms in MKL1 and CYP3A5 genes are associated with risk of CI-AKI

KU-046 improves cognitive function in vivo

Anaeropharma Science begins first-in-human trial of APS-001-F

Anthera Pharmaceuticals begins phase III CHABLIS-SC1 trial in lupus

Both primary endpoints met in pivotal study of Androxal

Novel phosphodiesterase inhibitors patented by Lundbeck

Japanese scientists design new ACC2 inhibitors

Novel Mnk1 inhibitors identified at Bayer

Invokana approved by the FDA for type 2 diabetes

NDA filed for hepatitis C candidate simeprevir

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...